The U.S. Food and Drug Administration (FDA) released its final guidance on the informed consent process for clinical trials on August 15, 2023. The new guidance is titled “Informed Consent: Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors”. This recent directive replaces the FDA’s 1998 guidance “A Guide to Informed Consent” and confirms its draft guidance, which was first proposed in July 2014. A review by Foley & Lardner LLP provides a detailed breakdown of the new final guidance.
Although the final guidance does not have legally binding effects, it outlines the FDA’s latest considerations on the process and necessary components of informed consent. Legal professionals who specialise in healthcare, life sciences and pharma law would be particularly interested in enhancing their understanding of these new guidances.
The significance of the informed consent in clinical trials cannot be overstated. It ensures the ethical and legal standards of research involving human subjects. It maintains the autonomy and well-being of participants by keeping them informed about the trials and their potential consequences, thus enabling them to make well-informed decisions about their voluntary participation.
The new guidance could also influence global clinical trial practices. As the FDA has vast influence in setting the standards for the healthcare and pharmaceutical sectors globally, legal professionals around the world should also take notice of these changes.